Skip to main content
All Posts By

admin

bhi-nih-logos

NIH AWARDS CONTRACT TO BIOHEALTH INNOVATION TO EXPAND ENTREPRENEUR-IN-RESIDENCE PROGRAM

By Uncategorized

BHI to Provide Qualified EIRs to NHLBI and NINDS

bhi-nih-logosBioHealth Innovation, Inc. (BHI) announced today that the National Institutes of Health (NIH) has signed an agreement to extend and expand its entrepreneur-in-residence (EIR) program with BHI. Under the terms of the new agreement, BHI is providing the services of five EIRs to the NIH starting with two lead institutes: the National Heart Lung and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS).

“BHI is excited to extend its existing relationship with NIH. By adding new EIRs within multiple institutes, we expand our ability to both support breakthrough technologies and to help identify new commercial opportunities working with national scientific experts,” said Richard Bendis, BHI President & CEO. “These new breakthroughs can then turn into new health-related products, many of which will come from the cutting-edge startup companies fostered by BHI that are focused on further enhancing the future of healthcare for all.”

Read More
enright-bill-vaxin-image

Vaxin to Acquire Immune Targeting Systems and Secures $16M in Committed Financing

By News Archive

enright-bill-vaxin-image

Moving to advance its leadership in developing vaccines for important public health and biodefense needs, Vaxin Inc. today announced that it has entered into a definitive agreement to acquire Immune Targeting Systems (ITS) Ltd. Vaxin is a clinical stage vaccine development company headquartered in Gaithersburg, Maryland. ITS develops novel T-cell vaccines at its operations in the United Kingdom and France. The deal is an all-stock transaction and is subject to customary closing conditions. The combined company will be known as Vaxin Inc.

Read More
disruption-corporation-logo

Disruption Corp. partnering with Greenspring Associates on venture analytics – Washington Business Journal

By News Archive

disruption-corporation-logo

Crystal City-based Disruption Corp. is partnering with Maryland-based Greenspring Associates, a $3 billion fund of funds that backs some venture capital firms that actively invest in the region, including New Enterprise Associates, Revolution Growth and True Ventures.

Ashton Newhall, co-founder of Greenspring Associates, told me he believes Disruption and Greenspring are “philosophically aligned” on the possibilities of using data analytics to make sounder investments in startups and the private market broadly.

Read More

138th Edition – February 17, 2015

By BHI Weekly Newsletter Archives





emocha-logo

Medication adherence smartphone and web system deployed for Tuberculosis patients

By Uncategorized

emocha-logo

We are pleased to announce that emocha Mobile Health launched its video-based directly observed therapy application, miDOT, in Harris County, Texas. miDOT will be used to bridge the distance between healthcare workers and the tuberculosis (TB) patients that are dispersed across the nearly 1,800 square miles surrounding Houston, which has one of the nation’s highest Tuberculosis rates. The roll-out began in early February after emocha won a competitive bidding process based on a head-to-head pilot with competing technologies.

Read More
mimetas

Organ on a Chip World Congress in Boston – Sponsored by BHI Client MIMETAS

By Uncategorized

July 8 – 9, 2015, Boston, MA, USA

The first ever Organ-on-a-Chip World Congress focuses on Organ-on-a-Chip technology, Biofabrication and 3D-Bioprinting in the life sciences. The conference will be held on 8-9 July 2015 in Boston, organized by Selectbio.

MIMETAS is corporate sponsor of this inaugural conference.

Oral Presentation Abstract Submission Deadline: February 27, 2015

Poster Submission Deadline: June 30, 2015

Read More
epidarex-capital-logo

World class drug discovery team launches new company to tackle chronic respiratory disease

By News Archive

epidarex-capital-logo

Enterprise Therapeutics Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. The proceeds will fund, in parallel, low molecular weight drug discovery and new target identification programs. The company will be based at the University of Sussex.

Read More
umd-ibbr-logo

RFP: GMP Facility – Institute for Bioscience and Biotechnology Research

By News Archive

umd-ibbr-logo

This is a Request for Proposal to lease the Good Manufacturing Practices (GMP) facility located at the Institute for Bioscience and Biotechnology Research (IBBR), on the University System of Maryland’s Shady Grove campus at 9600 Gudelsky Drive, Rockville, MD 20850.

IBBR is a University System of Maryland joint research enterprise between the University of Maryland College Park, The University of Maryland Baltimore and the National Institute of Standards and Technology. IBBR’s Vision and Mission are as follows:

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.